OKYO Pharma shares encouraging dry eye data OKYO Pharma Ltd (NASDAQ:OKYO) has shared encouraging results from a phase II trial of its treatment candidate for dry eye disease. The…
OKYO Pharma to include additional analyses in upcoming dry eye disease Key Opinion Leader event OKYO Pharma Ltd (NASDAQ:OKYO) announced that it is rescheduling its Key Opinion Leader event on the results of its Phase 2 trial…
OKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptoms OKYO Pharma Ltd (NASDAQ:OKYO) unveiled new results showing its lead drug OK-101 has shown significant and measurable improvements in various…
OKYO Pharma to host event featuring Phase 2 trial results for OK-101 in dry eye disease OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to host a Key Opinion Leader (KOL) event on April 9 following the…
OKYO Pharma to release Phase 2 dry eye disease trial results on Friday OKYO Pharma Ltd (NASDAQ:OKYO) announced that it will be releasing new and comprehensive data from its Phase 2 trial of…
OKYO Pharma to release Phase 2 dry eye disease trial results OKYO Pharma Ltd (NASDAQ:OKYO) announced that it will be releasing new and comprehensive data from its Phase 2 trial of…